Beleaguered Novo offers relief to investors, thanks to Wegovy pill
By Steve Goldstein
Novo Nordisk launched a pill version of Wegovy alongside the injectable version earlier this year.
Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
The 102-year-old company cited "increased expectations for GLP-1 product sales" as it lifted its 2026 outlook for both sales and adjusted operating profit growth to be in a range of -2% to 2%, at constant exchange rates - both about three percentage points higher than Wall Street expectations heading into its third-quarter report. Novo started the year warning that profits could fall between 5% and 13%.
It said third-quarter sales rose 6% to 79.19 billion Danish kroner ($11.9 billion), coming in 8% ahead of analyst estimates, according to FactSet. Its operating profit, though down 3% on the quarter, also beat projections.
The Wegovy pill accounted for 5.39 billion kroner in sales, about a quarter of what its injectable counterpart took in. Its injectable diabetes products, including Ozempic, accounted for 29.81 billion kroner of sales, down 5% year-on-year. Analysts at the research firm Alphavalue blamed pricing pressure and intense competition from Eli Lilly.
The stock (DK:NOVO.B) (NVO) gained 6% in early trading but is worth roughly one-quarter of what it was at its 2024 peak.
Novo also said its chief financial offer Karsten Munk Knudsen would step down, to be replaced by Luigi La Corte, previously of Swiss pharmaceutical company Galderma (CH:GALD).
"Overall, these results should provide some relief for Novo's beleaguered investors," said the Alphavalue team.
"The firm may return to a better growth from 2027 onwards and we see promising obesity/diabetes assets in Novo's pipeline as well, however, Novo's management in on the clock to diversify its offerings and avoid any patent cliff situation when Wegovy/Ozempic lose patents from 2031 onwards."
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-04-26 0441ET
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
United States